Search Results

PeploBio and IncellDX are launching the first laboratory developed test in the UK and EU to help diagnose Long COVID, providing doctors with accurate insights into personalised treatment approaches using the incellKINE Long Hauler Index technology.

IncellDx today announced Todd Pollard has joined its executive leadership team as Chief Operating Officer.

IncellDx today announced it has been granted U.S. Patent No. 11,180, 491 by the U.S. Patent and Trademark Office (“USPTO”) for methods of treating coronaviruses including COVID-19 (the “Patent”).

IncellDx, a precision medicine company, today announced the journal Frontiers in Immunology has published a study detailing a framework for understanding the potential mechanism of, and potential treatment for, Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.

IncellDx, Inc., a global leader in single-cell diagnostics, announces the USPTO has issued patent US10,782,298 to IncellDx.

IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer’s FDA-approved CCR5 antagonist Maraviroc.

IncellDx, Inc. and Biolidics have announced that they have signed a Distribution Agreement for the IncellDx bioINK® PD-L1 CTC Core Kit. Biolidics will distribute the product with the Biolidics’ ClearCell® FX1 System.

IncellDx, Inc., a global leader in single-cell diagnostics, announces the signing of an agreement with MD Biosciences, Inc. for the commercialization of novel assays based on IncellDx’s work on diagnostic, prognostic, and therapeutic biomarkers in COVID-19 and other cytokine storm conditions. Under the terms of the agreem

Factorial Diagnostics and IncellDx announced that they have agreed to terms on an exclusive license and supply agreement for technology that will enable the development of their multi-omic, cancer diagnostic workflow.

IncellDx, Inc., a global leader in single-cell diagnostics, announces approval by the Costa Rican Ministry of Health of its Next Generation HPV/cervical cancer assay, OncoTect 3Dx. This novel assay is the only test to simultaneously detect and quantify 3 molecular markers of cervical cancer—overexpression of oncogenes (E6, E7 mRNA), proliferation, and aneuploidy